Abstract: The present disclosure provides crystalline forms of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile, pharmaceutical compositions comprising the crystalline forms, methods of using the crystalline forms, and processes for making the crystalline forms.

Abstract: The present invention relates inter alia to expression vector production as well as application to the production of host cells for protein repertoire expression and high-throughput screening. The invention also relates to primers useful for PCR amplification of nucleotide sequences encoding human antibody variable domains.

Abstract: The present disclosure provides crystalline forms of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile, pharmaceutical compositions comprising the crystalline forms, methods of using the crystalline forms, and processes for making the crystalline forms.

Abstract: A promotion processing system may include a point-of-sale terminal at a store to collect purchased product identifiers from products being purchased, and a promotion generation server. The server may obtain the collected purchased product identifiers from the point-of-sale terminal, determine a store-transaction count based upon the collected purchased product identifiers, and for each purchased product identifier, map the corresponding product to an aisle location within the store. The server may determine a corresponding aisle-transaction count for the aisle location corresponding to each product based upon the mapped aisle locations, and determine shopper paths of travel within the store based upon the store- and aisle-transaction counts. The server may identify a location within the store for an aisle violator sign for a promoted product located in one of the aisle locations based upon the shopper paths of travel and the aisle-transaction counts, and generate a digital promotion for the promoted product.

Abstract: The present disclosure relates to high-throughput screening methods for identifying one or more chromatography operational parameters (e.g., binding parameters) and/or reagents for purifying EVs (e.g., exosomes) from a sample using chromatography. Also disclosed herein are methods for improving one or more aspects of EV (e.g., exosome) purification, e.g., improving EV yield, increasing EV ligand density, and/or reducing impurity recovery.

Abstract: This disclosure includes expandable spinal fusion implants, instrumentation, and methods for using the same.

Abstract: Systems and methods are disclosed for managing skin in a subterranean wellbore. In an embodiment, the method includes oscillating a drawdown pressure of the subterranean wellbore in a predetermined pattern that comprises a plurality of alternating drawdown pressure increases and drawdown pressure decreases. The drawdown pressure increases of the predetermined pattern comprise increasing the drawdown pressure at a first rate, and the drawdown pressure decreases of the predetermined pattern comprise decreasing the drawdown pressure at a second rate that is different from the first rate.

Abstract: A method of detecting conditions indicative of energy meter tampering, meter faults or energy loss (e.g. due to energy theft) is disclosed. The method includes receiving energy consumption data from an energy meter indicating consumption of energy at a location served by the energy meter. Event data is also received from the meter comprising one or more events generated by the energy meter. The consumption data is analysed to detect a predetermined consumption condition. The event data is analysed to detect a predetermined event or event pattern in the event data. An alert condition is generated in response to detecting both the consumption condition and the event or event pattern.

Abstract: The present invention relates inter alia to expression vector production as well as application to the production of host cells for protein repertoire expression and high-throughput screening. The invention also relates to primers useful for PCR amplification of nucleotide sequences encoding human antibody variable domains.

Abstract: The invention is related to the preparation of protected piperidine carboxylates suitable for use as intermediates that lead, via a series of additional process steps, including a sulfation of a hydroxy urea compound, to the preparation of the beta lactamase inhibitor (2S,5R)-7-oxo-N-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide.

Abstract: An encoder may be configured to receive a first input from a user. The encoder may include a first user input area. A configurator may be configured to communicate with the encoder and the encoder may be configured to communicate with a CPU. The encoder may receive the first input from the user at the first user input area based on an encoder configuration defined by the configurator. The encoder may communicate the first input to the CPU based on the encoder configuration defined by the configurator. A panel may be configured to receive a first input from a user. The panel may include a plurality of input areas. A portable computing device may comprise a configurator. The portable computing device may be configured to communicate with a CPU.

Abstract: An encoder may be configured to receive a first input from a user. The encoder may include a first user input area. A configurator may be configured to communicate with the encoder and the encoder may be configured to communicate with a CPU. The encoder may receive the first input from the user at the first user input area based on an encoder configuration defined by the configurator. The encoder may communicate the first input to the CPU based on the encoder configuration defined by the configurator. A panel may be configured to receive a first input from a user. The panel may include a plurality of input areas. A portable computing device may comprise a configurator. The portable computing device may be configured to communicate with a CPU.

Abstract: A smoking pipe for smoking a tobacco product has an elongated pipe body with a passage therethrough a mouthpiece portion at the first end of the pipe body and a chamber formed in the second end of the pipe body opposite to the mouthpiece portion. A cartridge removably supported within the chamber receives the tobacco product therein. The cartridge can be slidably removed to allow the chamber to be cleaned and refilled simply by removing the cartridge and replacing the cartridge with a new, clean cartridge having fresh smoking product optionally already packed therein. The pipe body may be optionally formed in two body sections joined to one another by respective magnetic couplers at the abutted inner ends of the two body sections.

Abstract: An encoder may be configured to receive a first input from a user. The encoder may include a first user input area. A configurator may be configured to communicate with the encoder and the encoder may be configured to communicate with a CPU. The encoder may receive the first input from the user at the first user input area based on an encoder configuration defined by the configurator. The encoder may communicate the first input to the CPU based on the encoder configuration defined by the configurator. A panel may be configured to receive a first input from a user. The panel may include a plurality of input areas. A portable computing device may comprise a configurator. The portable computing device may be configured to communicate with a CPU.

Abstract: The present invention comprises a polymeric based femoral and/or tibial component implant to be used in total knee replacement/arthroplasty procedures serving to provide increased wear resistance, enhanced physiological response at the bone/implant interface, and decreased stress-shielding. The implant can be made via additive manufacturing. The articulating surface of the implant may be implemented in without any additive or in a form containing an additive for improved tribological response. Further, the device disclosed herein contains an interfacial surface which is in contact with the native bone (i.e., bone/implant interface) which may exist in its pure form, containing a bioactive additive. The implant has a porous morphology on the bone/implant interface for improved biological response and improved fixation. The depth of the additives and the topographical morphology therein are controlled via techniques disclosed herein.

Abstract: An apparatus (12) for treating water, in particular for removing surfactants from waste water, includes a vessel (14), defining an inlet (16) for receiving waste water containing air bubbles, and an outlet (20) for the exit of water, following treatment. Inside the vessel there is at least one tubular member (50) having a lower open end (52) into which the flow of waste water from the inlet may be directed in use. The tubular member (50) extends from the inlet towards a top of the vessel where an upper exit (54) from the tubular member is defined. In use, most un-aerated water entering the vessel through the inlet can exit the tubular member at the lower open end. Foam formed in the water by the air bubbles may travel up the tubular member to the upper exit, which is preferably located above the water level (60) in the vessel.

Abstract: A point-to-multipoint non-addressed messaging processing system having a message processing system coupled to multiple message origination system for receiving message requests from message originating agents, each message request including a message agent identification identifying the message originator, a geographically defined transmission target area, a message type identifier uniquely identifying a message type, and a message, the message processing system verifying each received message request to provide a verified message, the verifying being a function of the message originating agent identification, and the message type identifier and then for each verified message request identifying a non-addressed message channel identifier, determining a point-to-multipoint non-addressed message transmission system serving at least a portion of the transmission target area of the message request for message type of the message type identifier, and transmitting the message, and the message type identifier, and t

Abstract: The present disclosure provides crystalline forms of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile, pharmaceutical compositions comprising the crystalline forms, methods of using the crystalline forms, and processes for making the crystalline forms.

Abstract: An encoder may be configured to receive a first input from a user. The encoder may include a first user input area. A configurator may be configured to communicate with the encoder and the encoder may be configured to communicate with a CPU. The encoder may receive the first input from the user at the first user input area based on an encoder configuration defined by the configurator. The encoder may communicate the first input to the CPU based on the encoder configuration defined by the configurator. A panel may be configured to receive a first input from a user. The panel may include a plurality of input areas. A portable computing device may comprise a configurator. The portable computing device may be configured to communicate with a CPU.